Lucentis Bests Laser in DME (CME/CE)
(MedPage Today) -- Patients with diabetic macular edema (DME) treated with the costly drug ranibizumab (Lucentis) reported more clinically meaningful improvement in visual functioning than those who received laser treatments alone, according to a new study. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - August 25, 2013 Category: Consumer Health News Source Type: news
Aflibercept for Exudative AMD Aflibercept for Exudative AMD
How do patients with exudative AMD with persistent fluid on OCT despite receiving regular ranibizumab and/or bevacizumab respond to aflibercept? The British Journal of Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 12, 2013 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news
NHS could save £84m using cheaper drug to prevent blindness, trial finds
Researchers say Avastin is just as good as more-expensive Lucentis for treating wet age-related macular degenerationThe NHS could save more than £84m a year if it used a cheap, unlicensed drug to treat people in danger of going blind rather than the expensive one currently licensed and promoted by leading pharmaceutical companies for the purpose, a ground-breaking trial has shown.Researchers led by Prof Usha Chakravarthy from Queen's University Belfast have finally provided an answer to the controversial question of whether the cancer drug Avastin can safely be used to treat people with wet age-related macular degeneratio...
Source: Guardian Unlimited Science - July 18, 2013 Category: Science Authors: Sarah Boseley Tags: The Guardian Pharmaceuticals industry News Health Medical research Society UK news Disability Blindness and visual impairment NHS Business Science Source Type: news
Avastin as Good as Lucentis for AMD (CME/CE)
(MedPage Today) -- Bevacizumab (Avastin) appears to have efficacy similar to that of ranibizumab (Lucentis) for the treatment of neovascular age-related macular degeneration, and monthly administration may offer some advantages over as-needed treatment, randomized trial results showed. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - July 18, 2013 Category: Consumer Health News Source Type: news
Ranibizumab Injections for Retinopathy of PrematurityRanibizumab Injections for Retinopathy of Prematurity
A new study reports on the 3-year outcomes of infants with ROP treated with intravitreal ranibizumab injections. Are they effective? The British Journal of Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 15, 2013 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news
Lucentis approved in EU
The European Commission has granted Novartis a new indication for Lucentis® (ranibizumab) to treat patients with visual impairment due to choroidal neovascularization (CNV) secondary to pathologic myopia (myopic CNV). (Source: Pharmacy Europe)
Source: Pharmacy Europe - July 9, 2013 Category: Drugs & Pharmacology Source Type: news
Novartis’ Lucentis gets EU approval to treat pathologic myopia
The European Commission has approved Novartis’ Lucentis (ranibizumab) for the treatment of visual impairment due to choroidal neovascularisation (CNV) secondary to pathologic myopia (myopic CNV). (Source: Drug Development Technology)
Source: Drug Development Technology - July 7, 2013 Category: Pharmaceuticals Source Type: news
Ranibizumab Approved in EU for Myopia ComplicationRanibizumab Approved in EU for Myopia Complication
A clinical trial has shown that patients with choroidal neovascularization generally experienced better vision after 1 injection of the vascular endothelial growth factor inhibitor. International Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 5, 2013 Category: Consumer Health News Tags: Ophthalmology News Alert Source Type: news
EU approves Novartis eye drug for new use
ZURICH (Reuters) - Swiss drugmaker Novartis' eye drug Lucentis has been approved as a treatment for a further condition related to worsening eyesight by the European Union, adding to three other conditions for which it is already approved. (Source: Reuters: Health)
Source: Reuters: Health - July 5, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
Pilot Study Has Promising Results For Age-Related Macular Degeneration
There is no cure for age-related macular degeneration, an eye disease that is the leading cause of vision loss and blindness in older Americans. Last year, the National Institutes of Health reported that two drugs injected into the eyes, Avastin and Lucentis, eased symptoms for sufferers, especially those in the advanced, "wet" stage of the disease, when blood vessels in the eye become swollen and leak fluids in the eye. Yet for some AMD patients, the two drugs either don't work for long or fail to work at all. It's a dead end for treatment, or so it seemed... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 21, 2013 Category: Consumer Health News Tags: Eye Health / Blindness Source Type: news
No Proof Of Added Benefit Found For Aflibercept In Wet Age-Related Macular Degeneration
Manufacturer's dossier did not contain any usable data for the comparison with ranibizumab The drug aflibercept (trade name: Eylea) has been approved in Germany since November 2012 for the treatment of wet age-related macular degeneration (AMD). In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG) the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new drug offers an added benefit over the current standard therapy... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 7, 2013 Category: Consumer Health News Tags: Eye Health / Blindness Source Type: news
Lucentis® receives positive opinion
Novartis has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for Lucentis® (ranibizumab) to treat patients with visual impairment due to choroidal neovascularisation (CNV) secondary to pathologic myopia (myopic CNV). (Source: Pharmacy Europe)
Source: Pharmacy Europe - June 4, 2013 Category: Drugs & Pharmacology Source Type: news
Bayer’s AMD drug to rival Lucentis after NICE recommendation
The National Institute of Health and Care Excellence in the UK has recommended Bayer's wet age-related macular degeneration (AMD) drug Eylea in its final draft guidance published today. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - May 30, 2013 Category: Pharmaceuticals Source Type: news
RVO: Reading Speed Improves With Ranibizumab Injections RVO: Reading Speed Improves With Ranibizumab Injections
Ranibizumab therapy makes a functional difference for patients with retinal vein occlusion, researchers have found. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 24, 2013 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Bevacizumab Cheaper Than Ranibizumab for Macular DegenerationBevacizumab Cheaper Than Ranibizumab for Macular Degeneration
Cost analysis favors one vascular endothelial growth factor inhibitor over another for patients with age-related macular degeneration. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 23, 2013 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
